The abstract is read at the publisher; the summary is JClub's.
GLP-1 receptor agonists and later multiagonist therapies have shifted obesity pharmacotherapy in the 2020s, with substantially greater efficacy, safety, and disease-modifying benefits than older agents.
- Why it matters: Obesity pharmacotherapy has been persistently underused due to stigma, early drug withdrawals over safety concerns, poor efficacy, and limited recognition of obesity as a chronic disease.
- What they did: The authors provide a critical historical analysis of obesity medication development, focusing on scientific, regulatory, and societal factors, and noting WHO’s global guidelines and Essential Medicines List inclusion of GLP-1 receptor agonists for a narrowly defined population.
- The result: This paradigm shift enabled broader recognition by WHO, supporting safer and more effective pharmacotherapy adoption, while highlighting remaining barriers to wide acceptance.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.